stockrowMiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024.
- Revenue
- −45.2%
- EPS
- −154.1%
- Free cash flow
- −87.2%
- Total debt
- −6.80%
Quarter to September 2026, against a year earlier
Follow MDXG
Alert me
MiMedx Group, Inc (MDXG) Altman Z-score
MiMedx Group, Inc's Altman Z-score for fiscal 2025 is 9.38, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 9.38 | (4.84) |
| FY2024 | 14.22 | 6.19 |
| FY2023 | 8.03 | 6.69 |
| FY2022 | 1.34 | (1.43) |
| FY2021 | 2.77 | (0.19) |
| FY2020 | 2.96 | (1.62) |
| FY2019 | 4.58 | 1.06 |
| FY2018 | 3.52 | (16.80) |
| FY2017 | 20.32 | 9.53 |
| FY2016 | 10.79 | (12.73) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.62 | — | 0.75 | |
| Retained earnings / total assets | (0.12) | — | −0.17 | |
| EBIT / total assets | 0.19 | — | 0.62 | |
| Market value of equity / total liabilities | 11.62 | — | 6.97 | |
| Sales / total assets | 1.22 | — | 1.22 | |
| Altman Z-score | Safe zone | 9.38 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 8.06 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | 10.3× |
| MDXG MiMedx Group, Inc | 9.4× |
| DMAC DiaMedica Therapeutics, Inc. compare | 6.7× |
| CTMX CytomX Therapeutics, Inc. compare | 0.9× |
| OVID Ovid Therapeutics compare | 0.2× |
| CBIO Crescent Biopharma, Inc. compare | −0.1× |
| RGNX REGENXBIO Inc. compare | −2.6× |
| INDP Indaptus Therapeutics, Inc. compare | — |
| ETRA Electra Therapeutics Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets